No Critical Interactions Between Ledipasvir/Sofosbuvir and Certain Key Antiretrovirals
Cinnamon Girl said
May 30, 2014
From the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19- 21, 2014, Washington, DC.
"Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers. Atripla had an affect on ledipasvir deemed not clinically relevant by the Gilead team".
From the 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, May 19- 21, 2014, Washington, DC.
"Ledipasvir/sofosbuvir, a fixed-dose coformulation of two direct-acting antivirals (DAAs) for HCV infection, did not have a clinically significant impact on five frequently used antiretrovirals--raltegravir, efavirenz, rilpivirine, and tenofovir/emtricitabine (TDF/FTC)--according to results of three studies in healthy volunteers. Atripla had an affect on ledipasvir deemed not clinically relevant by the Gilead team".
Full article...
http://www.natap.org/2014/Pharm/Pharm_06.htm